SLC5A2 and diabetes mellitus: The findings of a series of CVOTs on SGLT2 inhibitors have led to a reduction in the risk of HF-related events in a broad range of patient populations with cardiovascular and renal risks, irrespective of the patient’s diabetes status [12, 30–32].